Margetuximab + Trastuzumab + Physician's choice of chemotherapy.
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER-2 Positive Breast Cancer
Conditions
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Trial Timeline
Aug 24, 2015 → Jun 14, 2022
NCT ID
NCT02492711About Margetuximab + Trastuzumab + Physician's choice of chemotherapy.
Margetuximab + Trastuzumab + Physician's choice of chemotherapy. is a phase 3 stage product being developed by MacroGenics for HER-2 Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02492711. Target conditions include HER-2 Positive Breast Cancer, Metastatic Neoplasm.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02492711 | Phase 3 | Completed |
Competing Products
11 competing products in HER-2 Positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab + Capecitabine + Cisplatin | Celltrion | Phase 2 | 52 |
| eribulin + carboplatin + trastuzumab | Eisai | Phase 1/2 | 41 |
| Apatinib and S-1 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| V930 | Merck | Phase 1 | 33 |
| Everolimus + Vinorelbine + Trastuzumab | Novartis | Phase 2 | 52 |
| IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel | Novartis | Phase 1 | 33 |
| T-DM1 | Roche | Phase 2 | 52 |
| Trastuzumab + Paclitaxel + Epirubicin + Carboplatin | Roche | Phase 2 | 52 |
| palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant | Pfizer | Phase 3 | 76 |
| Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab | United Therapeutics | Phase 1/2 | 38 |
| Alisertib + Endocrine therapy | Puma Biotechnology | Phase 2 | 44 |